Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Real-Life Experience of the Combination of Daratumumab, Bortezomib, Melphalan, and Prednisone (DVMP) in Patients with Newly Diagnosed Multiple Myeloma Ineligible for Autologous Stem-Cell Transplantation

Amalia Domingo-González, Rafael Alonso Fernández, Ana Jiménez, Teresa De Soto Alvarez, Ana Lerma, Virginia Pradillo Fernandez, Gonzalo Benzo Callejo, Jose Sanchez-Pina, Elena Landete, Alberto Velasco, Marina Menéndez Cuevas, Mónica María López Riñón, Andrés Ramírez López, Alberto Lopez Garcia, María-Jesús Blanchard, Elham Askari

Blood (2023) 142 (Supplement 1): 4745.

https://doi.org/10.1182/blood-2023-186954

Published: 2023

Journal Articles

Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease

Blood (2023) 142 (Supplement 1): 1958.

https://doi.org/10.1182/blood-2023-179452

Published: 2023

Journal Articles

Large Scale Analysis of Autologous Stem Cell Transplantation for Multiple Myeloma Patients Older Than 65 Years

Adolfo Jesús Sáez Marín, Gema Hernández-Ibarburu, Rafael Alonso Fernández, Jose Maria Sanchez Pina, Paula Lázaro Del Campo, Ana Jimenez Ubieto, Clara Cuellar, Andrea Tamayo Soto, Reyes Mas Babio, Lucia Medina, Maria Calbacho, Rosa Ayala, Joaquin Martinez Lopez

Blood (2023) 142 (Supplement 1): 7064.

https://doi.org/10.1182/blood-2023-180923

Published: 2023

Journal Articles

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Experience with a Spanish Cohort

Blood (2022) 140 (Supplement 1): 4315–4317.

https://doi.org/10.1182/blood-2022-158538

Published: 2022

Journal Articles

Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease

Blood (2022) 140 (Supplement 1): 2101–2103.

https://doi.org/10.1182/blood-2022-167247

Published: 2022

Journal Articles

Triple Combination of Ruxolutinib, Nilotinib and Prednisone Is Safe and Shows Promising Activity for the Treatment of Myelofibrosis Patients, Results of a Phase Ib Clinical Trial (RUNIC)

Rosa Ayala, Rafael Alonso Fernández, Valentín Garcia Gutierrez, Alberto Alvarez-Larran, Santiago Osorio, Jose M. Sanchez, Gonzalo Carreño Gomez-Tarragona, María Teresa Gómez-Casares, Antonia Duran, Joaquín Martínez-López

Blood (2021) 138 (Supplement 1): 3655.

https://doi.org/10.1182/blood-2021-150240

Published: 2021

Journal Articles

Compassionate Use of Belantamab Mafodotin for Treatment of Patients with Relapsed/Refractory Multiple Myeloma Heavily Treated. Spanish Experience

Blood (2021) 138 (Supplement 1): 3775.

https://doi.org/10.1182/blood-2021-151267

Published: 2021

Journal Articles

Cereblon enhancer methylation and IMiD resistance in multiple myeloma

Blood (2021) 138 (18): 1721–1726.

https://doi.org/10.1182/blood.2020010452

Published: 2021

Includes: Supplemental data

Journal Articles

Making Clinical Decisions to Change Therapy Using Measurable Residual Disease Improves the Outcome in Multiple Myeloma

Joaquin Martinez Lopez, Rafael Alonso Fernández, Sandy W. Wong, MD, Rafael Rios, MD PhD, Nina Shah, MD, Maria Teresa Cedena Romero, MD PhD, Yanira Ruiz-Heredia, Jose M. Sanchez, MD, Santiago Barrio Garcia, PhD, Thomas Martin, III, MD, Jeffrey L. Wolf, MD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-140352

Published: 2020

Journal Articles

Enhancing the Immune Surveillance in Multiple Myeloma Via CDK4/6 Inhibition

Yan Xu, MD, Yao Yao, Woojun Daniel Park, Sanika Derebail, MS, Chandraditya Chakraborty, PhD, Shidai Mu, Rafael Alonso Fernández, Srikanth Talluri, PhD, Zuzana Chyra, PhD, Kenneth Wen, Qingsheng Yan, Osasenaga Idahor, Selene Cipri, Rao Prabhala, Kenneth Anderson, MD, Mehmet K. Samur, PhD, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-143327

Published: 2020

Journal Articles

YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma

Blood (2020) 136 (4): 468–479.

https://doi.org/10.1182/blood.2019004147

Published: 2020

Includes: Supplemental data

Journal Articles

Restoring Innate and Adaptive Immune Repertoire in Multiple Myeloma for Therapeutic Application

Rafael Alonso Fernández, MD, Laetitia Pierre-Louis, Rao Prabhala, Yan Xu, MD, Joaquin Martinez-Lopez, MD PhD, Takahiro Miyazaki, Mehmet Kemal Samur, PhD, Loui Madakamutil, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 4398.

https://doi.org/10.1182/blood-2019-128767

Published: 2019

Journal Articles

The Role of Antiviral Treatment in Hepatitis C Virus (HCV)-Driven Monoclonal Gammopathies

Alba Rodríguez García, María Linares, PhD, Nicolas Mennesson, Alfredo Pérez-Revilla, Ricardo Sanchez, PhD MD, Alejandra Leivas, PhD BS, MSc, Rafael Alonso Fernández, MD, Edith Bigot-Corbel, PhD, Sylvie Hermouet, Joaquin Martinez-Lopez, MD PhD

Blood (2019) 134 (Supplement_1): 5560.

https://doi.org/10.1182/blood-2019-126549

Published: 2019

Journal Articles

Immunofixation (IF) in Urine Is Really Necessary to Define Complete Remission in Multiple Myeloma (MM)? a Subanalysis from the Pethema/GEM2012MENOS65 Phase III Clinical Trial

Blood (2018) 132 (Supplement 1): 474.

https://doi.org/10.1182/blood-2018-99-115050

Published: 2018

Journal Articles

The Role of Hepatitis C Virus in the Development of Multiple Myeloma: A Case Study

Alba Rodríguez García, María Linares, PhD, Nicolas Mennesson, Beatriz Sanchez-Vega, PhD, Ricardo Sanchez, Rafael Alonso Fernandez, Edith Bigot-Corbel, PhD, Sylvie Hermouet, Joaquin Martinez Lopez, MD

Blood (2018) 132 (Supplement 1): 5592.

https://doi.org/10.1182/blood-2018-99-112842

Published: 2018

Journal Articles

Absence of Contribution to a Differential Outcome of the Stringent Complete Response IMWG Category Respect to the Conventional CR in Multiple Myeloma. a Validation Analysis Based on the Pethema/GEM2012MENOS65 Phase III Clinical Trial

Blood (2018) 132 (Supplement 1): 1943.

https://doi.org/10.1182/blood-2018-99-116604

Published: 2018

Journal Articles

Abnormalities in Mitochondrial DNA Copy Number Have Pathogenetic and Prognostic Implications in Multiple Myeloma

Blood (2017) 130 (Supplement 1): 4378.

https://doi.org/10.1182/blood.V130.Suppl_1.4378.4378

Published: 2017

Journal Articles

Maintenance Treatment with Lenalidomide for Multiple Myeloma Increases the Proportion of MRD Negative (Flow-/PET-CT-) Patients

Rafael Alonso Fernández, María Teresa Cedena, Rafael Rios, Javier Lopez Jimenez, Alejandro Sanz, Fernando Martín, Antonio Valeri, PhD, Juan Jose Lahuerta, Joaquin Martínez-López

Blood (2017) 130 (Supplement 1): 3098.

https://doi.org/10.1182/blood.V130.Suppl_1.3098.3098

Published: 2017

Journal Articles

Prognostic Impact of Molecular Response Assessed By Next-Generation Sequencing in a Large Cohort of Multiple Myeloma Patients

Beatriz Sanchez-Vega, PhD, Rafael Alonso, MD, Isabel Cuenca, Santiago Barrio, PhD, Yanira Ruiz-Heredia, Carlos Marin, Inmaculada Rapado, PhD, Cristina Jimenez, BSc, Xabier Aguirre, Rosa M. Ayala, MD PhD, Teresa Cedena, Bruno Paiva, PhD, Maria-Victoria Mateos, MD PhD, Laura Rosiñol, Joan Bladé, Jesus San Miguel, MD PhD, Ramon Garcia-Sanz, MD PhD, Juan José Lahuerta, MDPhD, Joaquín Martínez-López, MD PhD

Blood (2016) 128 (22): 3283.

https://doi.org/10.1182/blood.V128.22.3283.3283

Published: 2016

Journal Articles

Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to Bortezomib, Thalidomide and Dexamethasone (VTD) As Induction Therapy for the Treatment of Transplant Eligible Multiple Myeloma

Victor Jimenez-Zepeda, MD, Nizar J. Bahlis, MD, Peter Duggan, MD, Rafael Alonso, MD, Juan José Lahuerta, MD PhD, Antonio Valeri, Paola Neri, MD PhD, Jason Tay, MD FRCPC MSc, Joaquin Martinez-Lopez

Blood (2016) 128 (22): 4505.

https://doi.org/10.1182/blood.V128.22.4505.4505

Published: 2016

NARROW

Real-Life Experience of the Combination of Daratumumab, Bortezomib, Melphalan, and Prednisone (DVMP) in Patients with Newly Diagnosed Multiple Myeloma Ineligible for Autologous Stem-Cell Transplantation

Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease

Large Scale Analysis of Autologous Stem Cell Transplantation for Multiple Myeloma Patients Older Than 65 Years

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Experience with a Spanish Cohort

Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease

Triple Combination of Ruxolutinib, Nilotinib and Prednisone Is Safe and Shows Promising Activity for the Treatment of Myelofibrosis Patients, Results of a Phase Ib Clinical Trial (RUNIC)

Compassionate Use of Belantamab Mafodotin for Treatment of Patients with Relapsed/Refractory Multiple Myeloma Heavily Treated. Spanish Experience

Cereblon enhancer methylation and IMiD resistance in multiple myeloma

Making Clinical Decisions to Change Therapy Using Measurable Residual Disease Improves the Outcome in Multiple Myeloma

Enhancing the Immune Surveillance in Multiple Myeloma Via CDK4/6 Inhibition

YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma

Restoring Innate and Adaptive Immune Repertoire in Multiple Myeloma for Therapeutic Application

The Role of Antiviral Treatment in Hepatitis C Virus (HCV)-Driven Monoclonal Gammopathies

Immunofixation (IF) in Urine Is Really Necessary to Define Complete Remission in Multiple Myeloma (MM)? a Subanalysis from the Pethema/GEM2012MENOS65 Phase III Clinical Trial

The Role of Hepatitis C Virus in the Development of Multiple Myeloma: A Case Study

Absence of Contribution to a Differential Outcome of the Stringent Complete Response IMWG Category Respect to the Conventional CR in Multiple Myeloma. a Validation Analysis Based on the Pethema/GEM2012MENOS65 Phase III Clinical Trial

Abnormalities in Mitochondrial DNA Copy Number Have Pathogenetic and Prognostic Implications in Multiple Myeloma

Maintenance Treatment with Lenalidomide for Multiple Myeloma Increases the Proportion of MRD Negative (Flow-/PET-CT-) Patients

Prognostic Impact of Molecular Response Assessed By Next-Generation Sequencing in a Large Cohort of Multiple Myeloma Patients

Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to Bortezomib, Thalidomide and Dexamethasone (VTD) As Induction Therapy for the Treatment of Transplant Eligible Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only